Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Epoxide hydrolase 2 (EPHX2; CEH)

Cell culture and mouse studies suggest a combination of fish oil-derived epoxy docosapentaenoic acids (EDPs) and EPHX2 inhibitors could be useful for treating cancer. In a mouse model for breast cancer, EDP plus an EPHX2 inhibitor caused more potent inhibition of tumor vascularization and growth than either treatment alone. Next steps could include further preclinical evaluation of EPHX2 inhibitors in cancer models.
Arete Therapeutics Inc., a company cofounded by the study's corresponding author, had EPHX2 inhibitors in Phase II testing for type 2 diabetes before ceasing operations.

SciBX 6(16); doi:10.1038/scibx.2013.383
Published online April 25, 2013

Soluble epoxide hydrolase inhibitors patented; available for licensing from the University of California, Davis
Contact: Barbara Boczar, University of California, Davis, Calif.
e-mail:
baboczar@ucdavis.edu

Zhang, G. et al. Proc. Natl. Acad. Sci. USA; published online April 3, 2013;
doi:10.1073/pnas.1304321110
Contact: Bruce D. Hammock, University of California, Davis, Calif.
e-mail:
bdhammock@ucdavis.edu